Thrombotic diseases have threaten people's health seriously and the research of antithrombotic drugs has drawn wide attention.Inhibiting the P2Y~ receptor on platelet surface can prevent the happening of thrombus through inhibiting the aggregation of platelets.Therefore,studying P2Y12 receptor antagonists is an important direction towards antithrombosis therapy.Currently,clopidogrel,prasugrel,ticagrelor and cangrelor are the main P2Y12 receptor antagonists in clinical practice,which have achieved great therapeutic effect.However,they have their own disadvantages respectively.For example,clopidogrel resistance,increasing bleeding risk and limited application.Under this condition,the development of novel antiplatelet drugs is particularly important.ClopNPT as a novel P2Y12 receptor antagonist is in the research stage,which has shown desirable pharmacokinetic results and sufficient antiplatelet advantages.This article reviewed all the aspects above in research for P2Y12 receptor antagonists antiplatelet drugs.%血栓性疾病严重威胁人类的健康,抗血栓药物的研究备受关注.通过抑制血小板表面的P2Y12受体,可抑制血小板聚集反应,达到抗血栓的目的,因此研发P2Y12受体拮抗剂是治疗血栓疾病的一个重要方向.目前主要用于临床的P2Y12受体拮抗剂有氯吡格雷、普拉格雷、替格瑞洛和坎格雷洛,这些药物虽然在抗血栓方面取得良好的疗效,但是也有各自的不足之处,例如氯吡格雷抵抗、出血量增加风险、用途单一等.因此研发新颖的抗血小板药物显得尤为重要,ClopNPT作为新型P2Y12受体拮抗剂正在研究阶段,已经取得了良好的药动学实验结果,充分显示出抗血小板方面的优势.本文通过以上几个方面总结对比P2Y12受体拮抗剂类抗血小板药物的研究进展.
展开▼
